Introduction
Patients with progressive lymphoproliferative disorders, relapsed or refractory AML and poor-risk myelodysplastic syndrome (MDS) have a very poor outcome. Myeloablative conditioning and allogeneic stem cell transplantation offer a chance for cure; however, many patients, either owing to advanced age or coexisting medical conditions, are not suitable for this therapy because of the increased risk of TRM. [1] [2] [3] The recognition that the immune system by itself, without the need for myeloablative therapy, can provide disease control in some malignant haematological disorders led to the development of reduced-intensity conditioning (RIC) regimens. [4] [5] [6] [7] These regimens are particularly suitable for patients who would be considered unsuitable for a myeloablative-conditioned allogeneic haematopoietic stem cell transplantation (HSCT) because of their age and coexisting medical co-morbidities. The efficacy of such regimens in poor-risk haematological malignancies is established in the short to intermediate term; however, few data exist that assess disease-free survival beyond 4-5 years. [8] [9] [10] This report describes 79 consecutive patients with poorrisk myeloid and lymphoid malignancies treated with RIC regimens in preparation for allogeneic stem cell transplantation, with a median follow-up of 80 months from the date of transplantation for those patients alive after 3 years.
Materials and methods

Patients
Patients undergoing RIC between January 1999 and December 2005 were included in the analysis. The risk stratification was based as per the Accreditation Subcommittee of the European Bone Marrow Transplantation Registry criteria. 11 The AML patients were considered as poor risk if they had relapsed after initial therapy (4CR1) or had an unfavourable karyotype or had a delayed response to chemotherapy or history of preceding chemotherapy for neoplasia. [12] [13] [14] The low grade non-Hodgkin's lymphoma patients were considered as poor risk if they had progressive disease or early relapse after the firstline chemotherapy or had progressed after high-dose chemotherapy and autologous rescue or were unable to undergo autologous stem cell transplantation. Patients underwent RIC because of their advanced age (455 years), co-existence of medical co-morbidities and/or because of poor performance status.
Conditioning regimen. The conditioning regimen consisted of fludarabine 25 mg/m 2 daily for five days in combination with either (i) melphalan 140 mg/m 2 (n ¼ 56), (ii) CY 60 mg/ kg (n ¼ 21), (iii) cytarabine and idarubicin (n ¼ 1) or iv) anti-thymocytic globulin (ATG, Pfizer, Melrose Park, NSW, Australia) alone (n ¼ 1). Overall, thirty-six patients received equine ATG 15 mg/kg/day from day À4 to day þ 5 as a part of conditioning. All except one patient received G-CSF-mobilized peripheral blood stem cells. No ex vivo graft manipulation was performed.
GVHD and infection prophylaxis. The GVHD prophylaxis consisted of CsA at 3 mg/kg as a continuous i.v. infusion starting on day -1 and oral mycophenolate mofetil at 15 mg/kg bi-daily starting from day þ 1 to day þ 30 (n ¼ 36), with the CsA tapered from day þ 100 depending on the risk of GVHD. CsA alone was used in 17 patients; CsA in combination with MTX was used in 26 patients. Except for one patient, all patients receiving ATG received mycophenolate mofetil and CsA as post-transplant immunosuppression. Except for one patient, no patient receiving post-transplant MTX received ATG as a part of conditioning.
All patients were managed in a single HEPA-filtered isolation room in a dedicated ward. All patients with satisfactory engraftment received trimethoprim/sulphamethoxazole thrice per week along with ganciclovir. All patients received antifungal prophylaxis either with itraconazole or fluconazole. All patients on steroids or with active GVHD received oral penicillin. The CMV viral load was monitored by weekly quantitative PCR and pre-emptive therapy was instituted for patients with rising viral load.
Chimerism. In sex-mismatched transplants, karyotypic analysis was used to assess donor engraftment. In all others, PCR-based amplification of polymorphic short tandem repeat units unique to donors and recipients in CD3-positive cells and granulocytes was used. Full donor T-cell chimerism was defined as X95%.
Statistical analysis
Clinical data from 79 patients were analysed using Intercooled STATA version 9.2 and 10.1 (StataCorp, LP, TX, USA). Event-free survival (EFS) and OS were assessed using the Kaplan-Meier method and differences in each arm were compared using the log-rank test. The OS value was determined from the date of transplant until last follow-up or death. The EFS value was calculated from the date of transplant until relapse or death from any cause. Logistic regression analysis was used to estimate the relationship of clinical factors with mortality and the results were reported as odds ratios (95% confidence interval (CI)). Non-relapse mortality and relapse rates were estimated with cumulative incidence analysis, with each being a competing risk. OS and EFS were reported in months. All P-values were two tailed and a level of probability less than 0.05 was considered significant. The comparison of the arms was based on the intention-to-treat principle and data on all patients were analysed. The major end points of the analysis were disease-free survival (DFS), OS and EFS. As the 3-4-year follow-up data exist in the literature, 9, 15, 16 the results pertain mainly to those patients alive after 3 years.
Results
Patient characteristics and engraftment A total of 79 consecutive patients undergoing RIC for poor-risk myeloid and lymphoid malignancies at three transplant centres in Australia were included. Patient and disease characteristics are detailed in Table 1 . All patients had 100% donor engraftment by day þ 100. Median times to neutrophil and platelet engraftments were 14 (range: 7-27) days and 12 (range: 8-35) days, respectively. Engraftment kinetics varied on the basis of the GVHD prophylaxis used: median time to neutrophil engraftment was 13 (range: 7-20) days and 19 (range: 12-27) days, and the median time to platelet engraftment was 13 (range: 8-35) days and 20 (range: 14-33) days for patients treated with ATG and MTX, respectively. One patient in the ATG group and 11 in the MTX group failed to engraft platelets by day 30. Three patients died before engraftment. One patient, who had received the graft from a male sibling, had a delayed graft failure at six months. Overall, for the entire cohort, DFS and OS were 61.2% (95% CI: 45.1-73.9%) and 35.7% (95% CI: 25.0-46.6%), respectively.
Outcome up to 3 years. The DFS and OS at 3 years were 69.9% (95% CI: 54.7-80.5%) and 43.3% (95% CI: 32.0-52.9%), respectively ( Figure 1) . Overall, 18 patients relapsed within the first 3 years, the majority (14 of 18) succumbing to the disease. Two patients achieved a CR after donor lymphocyte infusion (DLI) but died from GVHD and fungal infections. One patient achieved a CR after DLI and remained in CR at 15 months after DLI. Three patients died from neutropenic sepsis very early posttransplant before engraftment. Overall, 31 patients died from transplant-related complications, the majority (20 of 31) within the first 100 days. The causes of early (by day þ 100) non-relapse mortality were GVHD and sepsisrelated multiorgan failure in eight patients, idiopathic pneumonia syndrome in two patients, and ischaemic bowel, secondary graft failure and progressive fungal infection in one patient. The cause of death of one patient was not known. One patient was lost to follow-up. No patient died between 1 and 3 years from transplant-related complications. Univariate analysis identified only the total nucleated cell (TNC) dose in the graft higher than the median value as Non-myeloablative allogeneic stem cell transplantation S Patil et al a statistically significant factor (odds ratio: 3.95; 95% CI: 1.2-12.3; P ¼ 0.01) for day 100 mortality, the median TNC dose being 664.00 Â 10 6 per kg (154À2236 Â 10 6 per kg). The other factors tested in univariate analysis were the use of ATG or MTX, donor and recipient age, CMV mismatch, donor type (sibling vs unrelated), sex-mismatch transplants, CD34 þ cell dose, disease state at transplant (CR or no CR), and number of pre-transplant therapies (4 or o2). None of these parameters was found to be of significance for non-relapse mortality.
Outcome beyond 3 years. Table 2 illustrates the outcome of patients in CR at 3 years. For the 28 patients alive at three years, the DFS and OS were 84.2% (95% CI: 62.1-94%) and 81.1% (95% CI: 59.7-91.9%), respectively, at a median follow-up of 80 months (48-112 months). Two patients have relapsed-one at 72 months with a recurrence of low-level paraprotein (original diagnosis of Waldenstrom's macroglobulinaemia), which has not required any treatment, and the second patient succumbed to relapsed AML at 48 months. One patient with CLL died at 70 months from metastatic prostate carcinoma, and was in molecular remission from CLL at the time of death. One patient died from an unknown cause at 58 months while in CR.
Outcome of patients not in CR at transplantation. Overall, 43 patients had morphologically/radiologically detectable disease at the time of transplantation (15 with follicular non Hodgkin's lymphoma, 6 patients with CLL/ small lymphocytic lymphoma, 12 with AML, 3 each with Hodgkin's lymphoma and T-cell non Hodgkin's lymphoma, and 4 patients with other lymphoproliferative disorders). In this group of patients with macroscopic disease at transplantation, 16 remained in CR beyond 3 years (illustrated in Table 2 ). Table 3 illustrates the outcome in different disease categories.
Disease-specific outcomes
AML/high-risk MDS. Fourteen of the 43 patients with high-risk myeloid malignancies remained in CR beyond 3 years; all maintaining ongoing CR at a median follow-up of 73 months. Of those in CR at three years, three late deaths were seen: one relapsed shortly afterwards and died a few weeks later after DLI, the second patient relapsed and succumbed to the disease at 48 months, and the third died at 58 months from infection.
CLL. Six patients with CLL underwent the RIC transplantation, two had an extensive marrow infiltrate at the time of transplantation and two had poor prognosis karyotypes (11q23 and 17p); the patient with 17p relapsed and succumbed to progressive disease. All others remained in molecular CR till the last follow-up. One patient died in remission from CLL at 72 months from metastatic prostatic carcinoma. and in CR beyond 3 years. One patient had relapsed at 21 months and is in ongoing remission at 18 months after DLI. Two patients had failed autografting. In this group of heavily pre-treated patients, treatment-related mortality was high (8 of 15): four deaths due to bacterial infection, two due to disseminated fungal infection, one due to idiopathic pneumonia syndrome and one due to GVHD. Influence of ATG Thirty-six patients received equine ATG as part of their conditioning. Thirteen were alive at three years and 12 were in CR at 3 years. Forty-three patients did not receive ATG as a part of conditioning. Two patients were lost to followup after 9 and 12 months. Fifteen were alive and in CR at 3 years. Overall, 10 patients treated with ATG relapsed À9 within 3 years after an allograft. In the non-ATG group, 9 patients relapsed-eight within three years. Fifteen out of 36 patients in the ATG group and 16 of 41 in the non-ATG group died from non-relapse causes. The median OS values were 13 and 12 months, and the median DFS values were 12 and 9 months for the ATG and non-ATG groups, respectively. The overall incidence of grade III-IV acute GVHD was higher in patients receiving ATG (33 vs 21%), but whether it was because of the higher number of unrelated donor transplants in the ATG group (18 vs 2) is unknown
Influence of MTX
As stated earlier, patients treated with MTX had a delayed engraftment. Excluding the patient who received both ATG and MTX, 25 patients did not receive ATG as a part of conditioning, but received four doses of MTX as posttransplant immunosuppression. Two patients were lost to follow-up at 9 and 12 months. Nine are alive and in CR beyond 3 years. Overall, four patients in this group relapsed, all within three years. Ten out of 23 patients died from non-relapse causes. Figure 2 highlight the outcomes in the MTX and ATG-treated groups.
Graft composition
The median CD34 þ cell dose for the entire cohort was 5.03 Â 10 6 per kg (1.7-17.37 Â 10 6 per kg); there was no difference in the CD34 þ cell dose between those in CR and those not in CR at 3 years (5.1 vs 4.9 Â 10 6 per kg). The median TNC dose for the entire cohort was 664 Â 10 6 per kg (154-2236 Â 10 6 per kg). The TNC dose was slightly higher in those relapsing or dead by 3 years than in those in CR at 3 years (743.1 vs 562 Â 10 6 per kg, P ¼ 0.15). As stated earlier, high TNC content was a risk factor for day 100 mortality (odds ratio: 3.9, 95% CI: 1.2-12.3).
Second neoplasms
One long-term survivor died of carcinoma prostate. At the time of his death, he was in remission from the original disease. No other patient developed a second noncutaneous malignancy. No post-transplant lymphoproliferative disorder was seen, even in those receiving ATG.
Discussion
When can the patients with high-risk haematological malignancies undergoing RIC allogeneic transplantation be considered to be cured? As most reported series present short-to intermediate-term outcome data (12-72 months), this question cannot be answered at present. Our report goes some way to reassure these patients. Our data show that for those alive and in remission at 3 years, the DFS and OS exceed 80%. This is comparable with the outcomes reported in the published literature after myeloablativeconditioned allogeneic transplantation. In patients with leukaemia undergoing myeloablative-conditioned allogeneic HSCT, Socie et al. 17 reported the relapse risk of 11% at 7 years for those in CR at 2 years. In a cohort of 1479 patients with various haematological malignancies, Bhatia et al. 18 have reported a mortality rate of 21% for those alive at 2 years after myeloablative-conditioned allogeneic HSCT. For those in CR at 3 years, our data show a comparable DFS and OS for patients treated with RIC allogeneic HSCT. Thus, it seems that in patients with high-risk myeloid and lymphoid malignancies treated with RIC, early disease control achieved by less intensive cytotoxic regimens and ongoing immunosurveillance by immunocompetent cells perhaps is qualitatively equivalent to that achieved by the addition of more intensive cytotoxic therapy.
Whether the RIC regimens should routinely be used to treat younger patients with fewer or no co-morbidities is unknown at this stage. In a retrospective analysis of 722 patients aged X50 years, Aoudjhane et al. 19 reported a similar relapse-free and overall survival after RIC and conventional myeloablative allograft (40 and 47% for RIC and 44 and 46% for myeloablative conditioning, respectively) at 2 years. Our data, in the high-risk cohort, show 3-year DFS, EFS and OS at 69.9%, 43.8% (95% CI: 32.5-54.6%) and 43.3%, respectively.
Myeloablative-conditioned allogeneic stem cell transplantation has been shown to provide a superior DFS in patients with AML and high-risk MDS, certainly in those with active disease at the time of transplantation; but with the patients in remission at the time of transplantation, there seems to be no difference in OS and DFS between myeloablative and RIC transplantation (at least till 3 years post-transplantation), suggesting that the allogeneic GVL effect may be more important than the intensity of the conditioning regimen in preventing relapses in patients with MDS or AML, who are in CR at the time of transplantation. [20] [21] [22] However, the importance of intensity of the conditioning regimens in the RIC transplants was highlighted by de Lima et al., 23 who, in a retrospective analysis of 94 patients with AML and MDS, showed a much lower risk of relapse at 40 months, even for those in CR at transplantation, in patients conditioned with fludarabine and melphalan as compared with fludarabine, cytarabine and idarubicin (30 vs 61%, respectively). All except one of the patients from our cohort, who achieved long-term remission received fludarabine and melphalan or CY. A larger series with a prospective comparison of various conditioning regimens will be needed to answer this question satisfactorily.
Development of chronic GVHD has been associated with a superior survival including DFS. 24 The majority of the long-term survivors in our cohort had developed some degree of chronic GVHD at some stage after HSCT. Importantly, most of these patients are functioning independently ( Table 2) .
As RIC transplantation is dependent on the GVL effect for long-term disease control, it would be reasonable to assume that the patients with active disease at the time of transplantation would have an unfavourable outcome. Our data suggest that, in the proportion of such patients, allogeneic transplantation conditioned with an RIC regimen does provide long-term disease control, 16 out of 43 remaining in CR after a median of 80 months following HSCT.
The use of ATG as a part of the conditioning regimens is controversial. In unrelated donor transplants, the use of ATG for in vivo T-cell depletion was found to be useful by some but not by others 25, 26 Bacigalupo et al. 27 reported a randomized prospective study of the use of ATG in unrelated donor marrow transplantation and found that though the risk of grade III-IV acute GVHD is markedly reduced in the ATG cohort, this does not result in the reduction of treatment-related mortality because of an increased risk of infections. They also noted that though the survival is unchanged, extensive chronic GVHD is significantly reduced in patients receiving ATG. Though the ATG group had a higher number of AML patients with active disease at the time of transplantation than those receiving MTX for GVHD prophylaxis (12 vs 1), our data suggest an equivalent EFS irrespective of the inclusion of ATG in the conditioning regimen. Not enough homogeneity existed in the lymphoma cohort to arrive at such a conclusion. All the patients with follicular lymphoma were heavily pre-treated and have a high mortality rate (8 of 15) when treated with fludarabine and melphalan/CY-based conditioned allogeneic HSCT. Khouri et al. 10 included rituximab in the conditioning regimen (along with fludarabine and cyclophosphamide but no ATG), and reported seven deaths in their cohort of 47 patients (as compared to 8 of 15 in our cohort). Importantly, in the report of Khouri et al. 10 as well as in our data, no patient has died from relapsed or progressive disease.
Cao et al 28 had reported an adverse outcome with a low CD8 þ T-cell dose in patients conditioned with an RIC. In our data, day 100, but not subsequent non-relapse mortality correlated with a higher TNC . This is a modifiable variable to reduce early TRM. Given the very low non-relapse mortality after day 100, this manoeuvre may have clinically relevant implications.
With the increasing use of more potent and non-selective immunosuppressive drugs (for example, alemtuzumab) for in vivo T-cell depletion, it would be interesting to see the data on long-term DFS in these patients. With a greater understanding of the various immunocompetent cells (natural killer cells, natural killer T cells, T-regulatory cells, dendritic cells), as well as a potential for the separation of GVL and GVH with G-CSF analogues, 29 perhaps the time has come for T subset separation or depletion rather than using non-selective agents.
The development of secondary cancers, including posttransplant lymphoproliferative disorder, in long-term survivors following myeloablative-conditioned allogeneic HSCT is well reported. 30 No such information is reported in the long-term survivors following an RIC allogeneic HCST. In our report, only one patient had developed a second solid tumour and no patient developed a post-transplant lymphoproliferative disorder. Whether RIC-conditioned allograft increases the risk of second neoplasms in this elderly cohort, whose baseline risk is higher, is an important unanswered question.
In conclusion, RIC-conditioned non-myeloablative allogeneic stem cell transplantation provides durable disease-free survival in patients with advanced myeloid and lymphoid malignancies. The majority of the long-term survivors function independently and have a good performance status. 
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Event free survival for allografts Figure 2 Event-free survival (EFS) in patients receiving MTX and ATGAM.
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